Hassaan Yousufi
Addiction Medicine · Rockville, MDNPI 1578192464
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 27.3% of the total.
Across 12 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$95
- Dexcom, Inc.$60
- Astellas Pharma US Inc$44
- Amgen$35
- Seqirus USA Inc$29
- Exact Sciences$29
- plus $56 from 3 others
What the payments were for
- Food & beverage$349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 1 | $95 |
| Dexcom, Inc. | 1 | $60 |
| Astellas Pharma US Inc | 2 | $44 |
| Amgen | 2 | $35 |
| Seqirus USA Inc | 2 | $29 |
| Exact Sciences | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Novo Nordisk | 1 | $18 |
| AstraZeneca | 1 | $14 |
How this compares
$349 in reported general payments places this provider in the 70th percentile of 34 addiction medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $15,368 |
| EliquisApixaban | 13 | $7,538 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $7,216 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $4,693 |
| Rosuvastatin Calcium | 33 | $760 |
| Levothyroxine Sodium | 33 | $758 |
| Atorvastatin Calcium | 78 | $731 |
| Ipratropium Bromide | 17 | $660 |
| Tamsulosin Hcl | 18 | $462 |
| Duloxetine Hcl | 15 | $425 |
| Losartan Potassium | 31 | $411 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $371 |
| Amlodipine Besylate | 54 | $347 |
| Gabapentin | 22 | $254 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $249 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Rockville
- Ahmed HeshmatRockville$3K
- Stanislav MalovRockville$110
- Mary Jo CannonHagerstown$791
- Carolyn ThangawngBaltimore$728
- Drew FullerGlen Burnie$612
- Sughanda KhannaOcean City$598
- Akinlawon AyeniLargo$596
- Gregory BurnettBaltimore$491
- Colleen CeremugaColumbia$426
- Paul KulpinskiBaltimore$425
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.